Skip to main content
      After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.
      RT @ejdein1: #EULAR Presentation 3478: Infection risk with surgeries:
      ⭐️Continue conventional DMARD
      ⭐️Some risk

      Eric Dein ejdein1

      4 years 5 months ago
      #EULAR Presentation 3478: Infection risk with surgeries: ⭐️Continue conventional DMARD ⭐️Some risk with biologics, may be confounder and no association with timing of infusions ⭐️Steroids are major risk factor! Esp >10 mg/d ⭐️Recommendations shown ⭐️Address other risks! @rheumnow https://t.co/Bi02d4p9Mw
      RT @uptoTate: COAST-Y 2 yr results: In r- and nr-axSpA, IXE tx led to consistent & sustained long-term improvements

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      COAST-Y 2 yr results: In r- and nr-axSpA, IXE tx led to consistent & sustained long-term improvements in disease activity & QoL. No new safety signals. #EULAR2021 poster #POS0912 @RheumNow https://t.co/W2YoyA4K14 https://t.co/lv0GLU2WTF
      RT @MeralElRamahiMD: #EULAR2021: Great talk by Dr. McFarland recapping the evidence for managing fibromyalgia.
      ➡️Ov

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      #EULAR2021: Great talk by Dr. McFarland recapping the evidence for managing fibromyalgia. ➡️Over a 6 month time period, costs were significantly lower for people receiving psychological therapies compared to those receiving usual care as shown by Cabral et al. @RheumNow https://t.co/RAkUSeNESy
      RT @ejdein1: Which drug are you most excited about changing future treatments in SLE? #EULAR2021 @RheumNow

      Eric Dein ejdein1

      4 years 5 months ago
      Which drug are you most excited about changing future treatments in SLE? #EULAR2021 @RheumNow
      RT @Janetbirdope: What is largest ⬆️ infection risk in RA? steroids, past infection, age, DM? Host factors & Pr

      Janet Pope Janetbirdope

      4 years 5 months ago
      What is largest ⬆️ infection risk in RA? steroids, past infection, age, DM? Host factors & Prednisone are Impt. Piling up risk factors is often multiplied! Biggest risk of serious infection and is recurrent serious infection! #EULAR2021 Meet the expert AbbVie session @RheumNow https://t.co/6m0OfsNF1W
      RT @uptoTate: Q-DAPSA (DAPSA + CRP), validated as a clinical measure of PsA disease activity in both practice & rese

      Dr. Rachel Tate uptoTate

      4 years 5 months ago
      Q-DAPSA (DAPSA + CRP), validated as a clinical measure of PsA disease activity in both practice & research from 5 centers in Berlin, 104 PsA pts. Let's get more studies to better understand the power of this measure. Poster #POS1069 #EULAR2021 @RheumNow https://t.co/X4UWGwH5i5 https://t.co/J7EpOjTjhe
      RT @RichardPAConway: Dr Lukas presents data showing possibility of tapering a range of TNF in AxSpA patients in remissio

      Richard Conway RichardPAConway

      4 years 5 months ago
      Dr Lukas presents data showing possibility of tapering a range of TNF in AxSpA patients in remission 162/184 (88.0%) LDA in progressive spacing group vs 173/189 (91.5%) in continued at 1 year.@RheumNow #EULAR2021 Abstr#0138
      RT @drdavidliew: Honoured to be part of the irAE session at #EULAR2021, with some great talks (and then also mine), incl

      David Liew drdavidliew

      4 years 5 months ago
      Honoured to be part of the irAE session at #EULAR2021, with some great talks (and then also mine), including: - Anne Bass @lovetolearn27 @HSpecialSurgery on irAE mechanisms - Maria Suarez-Almazor @MDAndersonNews on irAEs in the clinic Well worth tuning into! @RheumNow https://t.co/MN1IcLKv6u
      RT @MeralElRamahiMD: Abst#OP0137 at #EULAR2021:
      ➡️TNFi use for at least 1 year decreased radiographic sacroiliitis p

      Meral K. El Ramahi, MD MeralElRamahiMD

      4 years 5 months ago
      Abst#OP0137 at #EULAR2021: ➡️TNFi use for at least 1 year decreased radiographic sacroiliitis progression in early AxSpA in this ten year multicenter study of the German Spondyloarthritis Inception cohort (GESPIC) . ➡️This effect becomes evident 2-4 years after tx. @RheumNow https://t.co/GNnYqYmxhl
      RT @doctorRBC: SPACING trial: possible to taper TNFi in AxSpA pts in LDA
      ⭐️Tapering of TNFi in axSpA resulted in 88%

      Robert B Chao, MD doctorRBC

      4 years 5 months ago
      SPACING trial: possible to taper TNFi in AxSpA pts in LDA ⭐️Tapering of TNFi in axSpA resulted in 88% BASDAI<4 compared to 91.5% in unchanged group ⭐️adalimumab spaced out to q35 days Abs#OP0138 #EULAR2021 @RheumNow
      Check out this compilation of our EULAR 2021 Day 1 broadcasts below. You can follow the EULAR 2021 RheumNow podcasts on iTunes and Soundclound.com Listen by Clicking below: Day 1a Day 1b
      ×